Public trust in the pharma industry has taken a dip, according to recent data. Do actual patients agree?
At MM&M's annual conference, panelists talked about how healthcare is moving toward value-based care and accelerating innovation
How can manufacturers of special medications drive better patient outcomes in an increasing complex environment? Rick Ford, Senior Director, Market Access Solutions at TrialCard, provides expertise and insights.
At the Asembia Specialty Pharma summit, speakers described a healthcare ecosystem in which specialty products will represent nearly half of all drug spending.
Paul LeVine, VP, Analytic Services for TrialCard, describes proven strategies that prevent patient adherence fall off, driven by evidenced-based design and patient engagement programs.
Like other sectors, pharma is experiencing upheavals no one predicted, and as a result, drugs are being reviled for their price tags, rather than praised for their value.
Croom Lawrence and Kent Groves of Merkle Health explain being human.
Increasing patient engagement as a tool for improving care and outcomes has been a tough code to crack for the healthcare industry.
As with most drug pricing battles, patients yet again are caught in the crossfire.
With healthcare evolving from a fee-for-service system toward one that bases payment on outcomes, marketers must speak to customers in value-oriented messages.
Caregivers and patients predict how the use of AI will affect them.
Industry opponents say the end is nigh for pharma's ability to deduct expenses for consumer drug advertising, but those who've found their calling in healthcare comms ought to have something to say about that.
More than ever, marketers and agencies have a powerful role in shaping public health, curbing harmful behaviors, and promoting good ones among at-risk communities and individuals.
Senate committee votes in favor of Azar as new HHS head; FDA and DoD launch breakthrough designation program; Walmart offers free opioid disposal solution
New research calls into question the behavioral effects of some digital health tools.
Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018
Cancer Research UK's 'Right Now' brand campaign will return in 2018 with a new focus highlighting the impact that research has on people suffering with cancer.
Rather than talking at them, we need to design with and for them.
Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.
FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance
UnitedHealth Group to buy DaVita primary care unit for $4.9 billion; Roche drug combo doubles lung-cancer survival in trial; study: FDA programs expedite drug approval
Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds
U.K. to be first to sell OTC Viagra; Regeneron offers startup scientific expertise; docs more likely to get poor marks when they reject patient requests
More than half of doctors say patients make critical, racist, or sexist comments; Anthem to launch its own PBM; drugmakers face criticism for waste
Patients complain about positive healthcare ads; some drugmakers skirt Open Payment rules; new law requires disclosure of drug price hikes in California
Facebook itself has more than six million health-related groups.
The new brand campaign, Attacking Cancer from Every Angle, showcases all the services the organization provides.
600 patients are eligible for CAR-T therapy; the FDA halts Keytruda combo study for multiple myeloma; the regulator delays decision on Herceptin biosimilar
Patients are demanding more of their healthcare experience — and that includes from their healthcare providers, according to two new surveys.
As the influence of patient communities and advocacy groups grows, how can marketers work these organizations to achieve brand objectives?